Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Lossless Compression of Cytometric Data.

Bras AE, van der Velden VHJ.

Cytometry A. 2019 Oct;95(10):1108-1112. doi: 10.1002/cyto.a.23879. Epub 2019 Aug 20.

PMID:
31430053
2.

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.

Pfeifer H, Cazzaniga G, van der Velden VHJ, Cayuela JM, Schäfer B, Spinelli O, Akiki S, Avigad S, Bendit I, Borg K, Cavé H, Elia L, Reshmi SC, Gerrard G, Hayette S, Hermanson M, Juh A, Jurcek T, Chillón MC, Homburg C, Martinelli G, Kairisto V, Lange T, Lion T, Mueller MC, Pane F, Rai L, Damm-Welk C, Sacha T, Schnittger S, Touloumenidou T, Valerhaugen H, Vandenberghe P, Zuna J, Serve H, Herrmann E, Markovic S, Dongen JJMV, Ottmann OG.

Leukemia. 2019 Aug;33(8):1910-1922. doi: 10.1038/s41375-019-0413-0. Epub 2019 Mar 11.

PMID:
30858550
3.

MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.

Pott C, Brüggemann M, Ritgen M, van der Velden VHJ, van Dongen JJM, Kneba M.

Methods Mol Biol. 2019;1956:199-228. doi: 10.1007/978-1-4939-9151-8_9.

PMID:
30779036
4.

Flow cytometry diagnosis in myelodysplastic syndrome: Current practice in Latin America and comparison with other regions of the world.

Grille S, Iastrebner M, Lorand-Metze I, van der Velden VHJ, Ikoma MRV, Vidal-Senmache G, Colado E, Rabelo-Carrasco LJ, Blanco A, Huamán-Garaicoa F, O'Connor JE, Cao Pochintesta C, Jensen E, Bacal NS, Díaz L, Lens D.

Leuk Res. 2019 Apr;79:69-74. doi: 10.1016/j.leukres.2019.01.009. Epub 2019 Jan 24.

PMID:
30773246
5.

Combined cellular and soluble mediator analysis for improved diagnosis of vitreoretinal lymphoma.

de Hoog J, Dik WA, Lu L, Heezen KC, Ten Berge JC, Swagemakers SMA, van der Spek PJ, van Dongen JJM, van der Velden VHJ, Rothova A, Langerak AW.

Acta Ophthalmol. 2019 Sep;97(6):626-632. doi: 10.1111/aos.14036. Epub 2019 Jan 27.

PMID:
30688042
6.

Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?

Brooimans RA, van der Velden VHJ, Boeckx N, Slomp J, Preijers F, Te Marvelde JG, Van NM, Heijs A, Huys E, van der Holt B, de Greef GE, Kelder A, Schuurhuis GJ.

Leuk Res. 2019 Jan;76:39-47. doi: 10.1016/j.leukres.2018.11.014. Epub 2018 Nov 27.

7.

CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia.

Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC, Oussoren-Brockhoff YJM, Snel AN, Veldhuizen D, Scholten WJ, Maertens J, Breems DA, Pabst T, Manz MG, van der Velden VHJ, Slomp J, Preijers F, Cloos J, van de Loosdrecht AA, Löwenberg B, Valk PJM, Jongen-Lavrencic M, Ossenkoppele GJ, Schuurhuis GJ.

Leukemia. 2019 May;33(5):1102-1112. doi: 10.1038/s41375-018-0326-3. Epub 2018 Dec 12.

PMID:
30542144
8.

CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping.

Bras AE, de Haas V, van Stigt A, Jongen-Lavrencic M, Beverloo HB, Te Marvelde JG, Zwaan CM, van Dongen JJM, Leusen JHW, van der Velden VHJ.

Cytometry B Clin Cytom. 2019 Mar;96(2):134-142. doi: 10.1002/cyto.b.21745. Epub 2018 Nov 18.

9.

Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection.

Theunissen PMJ, de Bie M, van Zessen D, de Haas V, Stubbs AP, van der Velden VHJ.

Leuk Res. 2019 Jan;76:98-104. doi: 10.1016/j.leukres.2018.10.009. Epub 2018 Oct 22.

10.

Usability of femoral head bone marrow to verify reference ranges for the assessment of myelodysplasia by flow cytometry.

van Gammeren AJ, van Rijckevorsel M, Bras AE, Brandt-Hagens C, Te Marvelde JG, de Visser C, Joosen AMCP, Ermens AAM, van der Velden VHJ.

Int J Lab Hematol. 2018 Dec;40(6):726-733. doi: 10.1111/ijlh.12911. Epub 2018 Sep 2.

PMID:
30173422
11.

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study.

Flasinski M, Scheibke K, Zimmermann M, Creutzig U, Reinhardt K, Verwer F, de Haas V, van der Velden VHJ, von Neuhoff C, Zwaan CM, Reinhardt D, Klusmann JH.

Blood Adv. 2018 Jul 10;2(13):1532-1540. doi: 10.1182/bloodadvances.2018018945.

12.

Flow cytometry shows added value in diagnosing lymphoma in brain biopsies.

van der Meulen M, Bromberg JEC, Lam KH, Dammers R, Langerak AW, Doorduijn JK, Kros JM, van den Bent MJ, van der Velden VHJ.

Cytometry B Clin Cytom. 2018 Nov;94(6):928-934. doi: 10.1002/cyto.b.21641. Epub 2018 Sep 3.

13.

Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia.

Sędek Ł, Theunissen P, Sobral da Costa E, van der Sluijs-Gelling A, Mejstrikova E, Gaipa G, Sonsala A, Twardoch M, Oliveira E, Novakova M, Buracchi C, van Dongen JJM, Orfao A, van der Velden VHJ, Szczepański T; EuroFlow Consortium.

J Immunol Methods. 2018 Mar 9. pii: S0022-1759(17)30126-6. doi: 10.1016/j.jim.2018.03.005. [Epub ahead of print]

PMID:
29530508
14.

How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers.

Nováková M, Glier H, Brdičková N, Vlková M, Santos AH, Lima M, Roussel M, Flores-Montero J, Szczepanski T, Böttcher S, van der Velden VHJ, Fernandez P, Mejstříková E, Burgos L, Paiva B, van Dongen JJM, Orfao A, Kalina T.

J Immunol Methods. 2017 Nov 20. pii: S0022-1759(17)30139-4. doi: 10.1016/j.jim.2017.11.007. [Epub ahead of print]

PMID:
29154914
15.

Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia.

Lhermitte L, Mejstrikova E, van der Sluijs-Gelling AJ, Grigore GE, Sedek L, Bras AE, Gaipa G, Sobral da Costa E, Novakova M, Sonneveld E, Buracchi C, de Sá Bacelar T, Te Marvelde JG, Trinquand A, Asnafi V, Szczepanski T, Matarraz S, Lopez A, Vidriales B, Bulsa J, Hrusak O, Kalina T, Lecrevisse Q, Martin Ayuso M, Brüggemann M, Verde J, Fernandez P, Burgos L, Paiva B, Pedreira CE, van Dongen JJM, Orfao A, van der Velden VHJ.

Leukemia. 2018 Apr;32(4):874-881. doi: 10.1038/leu.2017.313. Epub 2017 Nov 1.

16.

Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients.

Hanekamp D, Denys B, Kaspers GJL, Te Marvelde JG, Schuurhuis GJ, De Haas V, De Moerloose B, de Bont ES, Zwaan CM, de Jong A, Depreter B, Lammens T, Philippé J, Cloos J, van der Velden VHJ.

Br J Haematol. 2018 Nov;183(3):512-516. doi: 10.1111/bjh.14991. Epub 2017 Oct 26. No abstract available.

PMID:
29076143
17.

Antigen receptor sequencing of paired bone marrow samples shows homogeneous distribution of acute lymphoblastic leukemia subclones.

Theunissen PMJ, van Zessen D, Stubbs AP, Faham M, Zwaan CM, van Dongen JJM, Van Der Velden VHJ.

Haematologica. 2017 Nov;102(11):1869-1877. doi: 10.3324/haematol.2017.171454. Epub 2017 Aug 31.

18.

The MLL recombinome of acute leukemias in 2017.

Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, Sutton R, Venn NC, Emerenciano M, Pombo-de-Oliveira MS, Barbieri Blunck C, Almeida Lopes B, Zuna J, Trka J, Ballerini P, Lapillonne H, De Braekeleer M, Cazzaniga G, Corral Abascal L, van der Velden VHJ, Delabesse E, Park TS, Oh SH, Silva MLM, Lund-Aho T, Juvonen V, Moore AS, Heidenreich O, Vormoor J, Zerkalenkova E, Olshanskaya Y, Bueno C, Menendez P, Teigler-Schlegel A, Zur Stadt U, Lentes J, Göhring G, Kustanovich A, Aleinikova O, Schäfer BW, Kubetzko S, Madsen HO, Gruhn B, Duarte X, Gameiro P, Lippert E, Bidet A, Cayuela JM, Clappier E, Alonso CN, Zwaan CM, van den Heuvel-Eibrink MM, Izraeli S, Trakhtenbrot L, Archer P, Hancock J, Möricke A, Alten J, Schrappe M, Stanulla M, Strehl S, Attarbaschi A, Dworzak M, Haas OA, Panzer-Grümayer R, Sedék L, Szczepański T, Caye A, Suarez L, Cavé H, Marschalek R.

Leukemia. 2018 Feb;32(2):273-284. doi: 10.1038/leu.2017.213. Epub 2017 Jul 13.

19.

Understanding the reconstitution of the B-cell compartment in bone marrow and blood after treatment for B-cell precursor acute lymphoblastic leukaemia.

Theunissen PMJ, van den Branden A, Van Der Sluijs-Gelling A, De Haas V, Beishuizen A, van Dongen JJM, Van Der Velden VHJ.

Br J Haematol. 2017 Jul;178(2):267-278. doi: 10.1111/bjh.14685. Epub 2017 May 25.

PMID:
28542787
20.

Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.

Theunissen PMJ, Sedek L, De Haas V, Szczepanski T, Van Der Sluijs A, Mejstrikova E, Nováková M, Kalina T, Lecrevisse Q, Orfao A, Lankester AC, van Dongen JJM, Van Der Velden VHJ; EuroFlow Consortium.

Br J Haematol. 2017 Jul;178(2):257-266. doi: 10.1111/bjh.14682. Epub 2017 Apr 17.

PMID:
28419441
21.

Lot-to-lot stability of antibody reagents for flow cytometry.

Böttcher S, van der Velden VHJ, Villamor N, Ritgen M, Flores-Montero J, Murua Escobar H, Kalina T, Brüggemann M, Grigore G, Martin-Ayuso M, Lecrevisse Q, Pedreira CE, van Dongen JJM, Orfao A.

J Immunol Methods. 2017 Mar 30. pii: S0022-1759(17)30075-3. doi: 10.1016/j.jim.2017.03.018. [Epub ahead of print]

PMID:
28365329
22.

Optimization and testing of dried antibody tube: The EuroFlow LST and PIDOT tubes as examples.

van der Velden VH, Flores-Montero J, Perez-Andres M, Martin-Ayuso M, Crespo O, Blanco E, Kalina T, Philippé J, Bonroy C, de Bie M, Te Marvelde J, Teodosio C, Corral Mateos A, Kanderová V, van der Burg M, Van Hoof D, van Dongen JJ, Orfao A.

J Immunol Methods. 2017 Mar 22. pii: S0022-1759(17)30095-9. doi: 10.1016/j.jim.2017.03.011. [Epub ahead of print]

23.

Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL.

Kotrova M, van der Velden VHJ, van Dongen JJM, Formankova R, Sedlacek P, Brüggemann M, Zuna J, Stary J, Trka J, Fronkova E.

Bone Marrow Transplant. 2017 Jul;52(7):962-968. doi: 10.1038/bmt.2017.16. Epub 2017 Feb 27.

PMID:
28244980
24.

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.

Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S, van der Velden VHJ, Pérez-Morán JJ, Vidriales MB, García-Sanz R, Jimenez C, González M, Martínez-López J, Corral-Mateos A, Grigore GE, Fluxá R, Pontes R, Caetano J, Sedek L, Del Cañizo MC, Bladé J, Lahuerta JJ, Aguilar C, Bárez A, García-Mateo A, Labrador J, Leoz P, Aguilera-Sanz C, San-Miguel J, Mateos MV, Durie B, van Dongen JJM, Orfao A.

Leukemia. 2017 Oct;31(10):2094-2103. doi: 10.1038/leu.2017.29. Epub 2017 Jan 20.

25.

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.

Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M, Sobral da Costa E, Kotrová M, Novakova M, Sonneveld E, Buracchi C, Bonaccorso P, Oliveira E, Te Marvelde JG, Szczepanski T, Lhermitte L, Hrusak O, Lecrevisse Q, Grigore GE, Froňková E, Trka J, Brüggemann M, Orfao A, van Dongen JJ, van der Velden VH; EuroFlow Consortium.

Blood. 2017 Jan 19;129(3):347-357. doi: 10.1182/blood-2016-07-726307. Epub 2016 Nov 30.

26.

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.

Boer JM, Steeghs EM, Marchante JR, Boeree A, Beaudoin JJ, Beverloo HB, Kuiper RP, Escherich G, van der Velden VH, van der Schoot CE, de Groot-Kruseman HA, Pieters R, den Boer ML.

Oncotarget. 2017 Jan 17;8(3):4618-4628. doi: 10.18632/oncotarget.13492.

27.

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Westers TM, Cremers EM, Oelschlaegel U, Johansson U, Bettelheim P, Matarraz S, Orfao A, Moshaver B, Brodersen LE, Loken MR, Wells DA, Subirá D, Cullen M, Te Marvelde JG, van der Velden VH, Preijers FW, Chu SC, Feuillard J, Guérin E, Psarra K, Porwit A, Saft L, Ireland R, Milne T, Béné MC, Witte BI, Della Porta MG, Kern W, van de Loosdrecht AA; IMDSFlow Working Group.

Haematologica. 2017 Feb;102(2):308-319. doi: 10.3324/haematol.2016.147835. Epub 2016 Oct 6.

28.

Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences.

Waanders E, Scheijen B, Jongmans MC, Venselaar H, van Reijmersdal SV, van Dijk AH, Pastorczak A, Weren RD, van der Schoot CE, van de Vorst M, Sonneveld E, Hoogerbrugge N, van der Velden VH, Gruhn B, Hoogerbrugge PM, van Dongen JJ, Geurts van Kessel A, van Leeuwen FN, Kuiper RP.

Leukemia. 2017 Apr;31(4):821-828. doi: 10.1038/leu.2016.277. Epub 2016 Oct 13.

PMID:
27733777
29.

Decreased IL7Rα and TdT expression underlie the skewed immunoglobulin repertoire of human B-cell precursors from fetal origin.

Rother MB, Jensen K, van der Burg M, van de Bovenkamp FS, Kroek R, van IJcken WF, van der Velden VH, Cupedo T, Olstad OK, van Dongen JJ, van Zelm MC.

Sci Rep. 2016 Sep 23;6:33924. doi: 10.1038/srep33924.

30.

Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes.

Cremers EM, Westers TM, Alhan C, Cali C, Visser-Wisselaar HA, Chitu DA, van der Velden VH, Te Marvelde JG, Klein SK, Muus P, Vellenga E, de Greef GE, Legdeur MC, Wijermans PW, Stevens-Kroef MJ, Silva-Coelho PD, Jansen JH, Ossenkoppele GJ, van de Loosdrecht AA; A study on behalf of the HOVON89 study group.

Haematologica. 2017 Feb;102(2):320-326. doi: 10.3324/haematol.2016.147843. Epub 2016 Sep 22.

31.

CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy.

Bras AE, Beishuizen A, Langerak AW, Jongen-Lavrencic M, Te Marvelde JG, van den Heuvel-Eibrink MM, Zwaan CM, van Dongen JJM, van der Velden VHJ.

Br J Haematol. 2018 Jan;180(2):292-296. doi: 10.1111/bjh.14310. Epub 2016 Sep 8. No abstract available.

PMID:
27604396
32.

New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B-cell precursor acute lymphoblastic leukaemia.

van der Velden VH, de Launaij D, de Vries JF, de Haas V, Sonneveld E, Voerman JS, de Bie M, Revesz T, Avigad S, Yeoh AE, Swagemakers SM, Eckert C, Pieters R, van Dongen JJ.

Br J Haematol. 2016 Mar;172(5):769-81. doi: 10.1111/bjh.13887. Epub 2015 Dec 21.

PMID:
26898195
33.

Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow cytometry.

Matarraz S, Almeida J, Flores-Montero J, Lécrevisse Q, Guerri V, López A, Bárrena S, Van Der Velden VHJ, Te Marvelde JG, Van Dongen JJM, Orfao A.

Cytometry B Clin Cytom. 2017 May;92(3):218-227. doi: 10.1002/cyto.b.21219. Epub 2015 Aug 18. Review.

34.

Fifteen years of external quality assessment in leukemia/lymphoma immunophenotyping in The Netherlands and Belgium: A way forward.

Preijers FW, van der Velden VH, Preijers T, Brooimans RA, Marijt E, Homburg C, van Montfort K, Gratama JW; Section Immunological and Molecular Cell Diagnostics of the Foundation for Quality Assessment in Medical Laboratories(SKML).

Cytometry B Clin Cytom. 2016 May;90(3):267-78. doi: 10.1002/cyto.b.21266. Epub 2015 Jul 31.

35.

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

van Dongen JJ, van der Velden VH, Brüggemann M, Orfao A.

Blood. 2015 Jun 25;125(26):3996-4009. doi: 10.1182/blood-2015-03-580027. Epub 2015 May 21. Review.

36.

Effect of a stable Angiotensin-(1-7) analogue on progenitor cell recruitment and cardiovascular function post myocardial infarction.

Sevá Pessôa B, Becher PM, Van Veghel R, De Vries R, Tempel D, Sneep S, Van Beusekom H, Van Der Velden VH, Westermann D, Danser AH, Roks AJ.

J Am Heart Assoc. 2015 Feb 5;4(2). pii: e001510. doi: 10.1161/JAHA.114.001510. Erratum in: J Am Heart Assoc. 2015 Apr;4(4). pii: e000649. doi: 10.1161/JAHA.115.000649.

37.

Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood.

Aalbers AM, van den Heuvel-Eibrink MM, Baumann I, Dworzak M, Hasle H, Locatelli F, De Moerloose B, Schmugge M, Mejstrikova E, Nováková M, Zecca M, Zwaan CM, Te Marvelde JG, Langerak AW, van Dongen JJ, Pieters R, Niemeyer CM, van der Velden VH.

Haematologica. 2015 Mar;100(3):315-23. doi: 10.3324/haematol.2014.107706. Epub 2014 Nov 25.

38.

Quality assessment program for EuroFlow protocols: summary results of four-year (2010-2013) quality assurance rounds.

Kalina T, Flores-Montero J, Lecrevisse Q, Pedreira CE, van der Velden VH, Novakova M, Mejstrikova E, Hrusak O, Böttcher S, Karsch D, Sędek Ł, Trinquand A, Boeckx N, Caetano J, Asnafi V, Lucio P, Lima M, Helena Santos A, Bonaccorso P, van der Sluijs-Gelling AJ, Langerak AW, Martin-Ayuso M, Szczepański T, van Dongen JJ, Orfao A.

Cytometry A. 2015 Feb;87(2):145-56. doi: 10.1002/cyto.a.22581. Epub 2014 Oct 23.

39.

A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR.

White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, Barbany G, Boeckx N, Bench A, Catherwood M, Cayuela JM, Chudleigh S, Clench T, Colomer D, Daraio F, Dulucq S, Farrugia J, Fletcher L, Foroni L, Ganderton R, Gerrard G, Gineikienė E, Hayette S, El Housni H, Izzo B, Jansson M, Johnels P, Jurcek T, Kairisto V, Kizilors A, Kim DW, Lange T, Lion T, Polakova KM, Martinelli G, McCarron S, Merle PA, Milner B, Mitterbauer-Hohendanner G, Nagar M, Nickless G, Nomdedéu J, Nymoen DA, Leibundgut EO, Ozbek U, Pajič T, Pfeifer H, Preudhomme C, Raudsepp K, Romeo G, Sacha T, Talmaci R, Touloumenidou T, Van der Velden VH, Waits P, Wang L, Wilkinson E, Wilson G, Wren D, Zadro R, Ziermann J, Zoi K, Müller MC, Hochhaus A, Schimmel H, Cross NC, Emons H.

Leukemia. 2015 Feb;29(2):369-76. doi: 10.1038/leu.2014.217. Epub 2014 Jul 18.

40.

Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS.

Porwit A, van de Loosdrecht AA, Bettelheim P, Brodersen LE, Burbury K, Cremers E, Della Porta MG, Ireland R, Johansson U, Matarraz S, Ogata K, Orfao A, Preijers F, Psarra K, Subirá D, Valent P, van der Velden VH, Wells D, Westers TM, Kern W, Béné MC.

Leukemia. 2014 Sep;28(9):1793-8. doi: 10.1038/leu.2014.191. Epub 2014 Jun 12.

PMID:
24919805
41.

B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma.

van der Velden VH, Hoogeveen PG, de Ridder D, Schindler-van der Struijk M, van Zelm MC, Sanders M, Karsch D, Beverloo HB, Lam K, Orfao A, Lugtenburg PJ, Böttcher S, van Dongen JJ, Langerak AW, Kappers-Klunne M, van Lom K.

Blood. 2014 Jul 17;124(3):412-9. doi: 10.1182/blood-2013-10-533869. Epub 2014 Jun 2.

PMID:
24891323
42.

T-cell receptor Vβ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS.

Aalbers AM, van den Heuvel-Eibrink MM, Baumann I, Beverloo HB, Driessen GJ, Dworzak M, Fischer A, Göhring G, Hasle H, Locatelli F, De Moerloose B, Noellke P, Schmugge M, Stary J, Yoshimi A, Zecca M, Zwaan CM, van Dongen JJ, Pieters R, Niemeyer CM, van der Velden VH, Langerak AW.

Blood Cancer J. 2014 May 2;4:e209. doi: 10.1038/bcj.2014.28.

43.

A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.

Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, van der Velden VHJ, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJM, Bindels EMJ, de Laat W, Delwel R.

Cell. 2014 Apr 10;157(2):369-381. doi: 10.1016/j.cell.2014.02.019. Epub 2014 Apr 3.

44.

Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia.

van der Veer A, van der Velden VH, Willemse ME, Hoogeveen PG, Petricoin EF, Beverloo HB, Escherich G, Horstmann MA, Pieters R, den Boer ML.

Blood Cancer J. 2014 Feb 14;4:e181. doi: 10.1038/bcj.2014.5. No abstract available.

45.

Minimal residual disease diagnostics in acute lymphoblastic leukaemia: impact of primer characteristics and size of junctional regions.

van der Velden VH, Noordijk R, Brussee M, Hoogeveen PG, Homburg C, de Haas V, van der Schoot CE, van Dongen JJ.

Br J Haematol. 2014 Feb;164(3):451-3. doi: 10.1111/bjh.12621. Epub 2013 Oct 26. No abstract available.

PMID:
24164448
46.

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, Maertens J, Boeckx N, de Greef GE, Valk PJ, Preijers FW, Huijgens PC, Dräger AM, Schanz U, Jongen-Lavrecic M, Biemond BJ, Passweg JR, van Gelder M, Wijermans P, Graux C, Bargetzi M, Legdeur MC, Kuball J, de Weerdt O, Chalandon Y, Hess U, Verdonck LF, Gratama JW, Oussoren YJ, Scholten WJ, Slomp J, Snel AN, Vekemans MC, Löwenberg B, Ossenkoppele GJ, Schuurhuis GJ.

J Clin Oncol. 2013 Nov 1;31(31):3889-97. doi: 10.1200/JCO.2012.45.9628. Epub 2013 Sep 23.

PMID:
24062400
47.

Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group.

Coenen EA, Zwaan CM, Reinhardt D, Harrison CJ, Haas OA, de Haas V, Mihál V, De Moerloose B, Jeison M, Rubnitz JE, Tomizawa D, Johnston D, Alonzo TA, Hasle H, Auvrignon A, Dworzak M, Pession A, van der Velden VH, Swansbury J, Wong KF, Terui K, Savasan S, Winstanley M, Vaitkeviciene G, Zimmermann M, Pieters R, van den Heuvel-Eibrink MM.

Blood. 2013 Oct 10;122(15):2704-13. doi: 10.1182/blood-2013-02-485524. Epub 2013 Aug 23.

48.

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.

van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, van der Velden VH, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML.

Blood. 2013 Oct 10;122(15):2622-9. doi: 10.1182/blood-2012-10-462358. Epub 2013 Aug 23.

49.

Monitoring antigen-specific biologics: current knowledge and future prospects.

Zandvliet ML, van Bezooijen JS, Bos MA, Prens EP, van Doorn M, Bijen I, Schreurs MW, van der Velden VH, Koch BC, van Gelder T.

Ther Drug Monit. 2013 Oct;35(5):588-94. doi: 10.1097/FTD.0b013e318295f6b2. Review.

PMID:
23942545
50.

Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting.

Feller N, van der Velden VH, Brooimans RA, Boeckx N, Preijers F, Kelder A, de Greef I, Westra G, Te Marvelde JG, Aerts P, Wind H, Leenders M, Gratama JW, Schuurhuis GJ.

Blood Cancer J. 2013 Aug 2;3:e129. doi: 10.1038/bcj.2013.27.

Supplemental Content

Loading ...
Support Center